Human Immunodeficiency Virus Type 1 gp41 Antibodies That Mask Membrane Proximal Region Epitopes: Antibody Binding Kinetics, Induction, and Potential for Regulation in Acute Infection

ABSTRACT Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency virus type 1 (HIV-1) envelope g41 cluster II membrane proximal external region (MPER) broadly neutralize HIV-1 primary isolates. However, these antibody specificities are rare, are not induced by Env immunization or HIV-1 infection, and are polyspecific and also react with lipids such as cardiolipin or phosphatidylserine. To probe MPER anti-gp41 antibodies that are produced in HIV-1 infection, we have made two novel murine MAbs, 5A9 and 13H11, against HIV-1 gp41 envelope that partially cross-blocked 2F5 MAb binding to Env but did not neutralize HIV-1 primary isolates or bind host lipids. Competitive inhibition assays using labeled 13H11 MAb and HIV-1-positive patient plasma samples demonstrated that cluster II 13H11-blocking plasma antibodies were made in 83% of chronically HIV-1 infected patients and were acquired between 5 to 10 weeks after acute HIV-1 infection. Both the mouse 13H11 MAb and the three prototypic cluster II human MAbs (98-6, 126-6, and 167-D) blocked 2F5 binding to gp41 epitopes to variable degrees; the combination of 98-6 and 13H11 completely blocked 2F5 binding. These data provide support for the hypothesis that in some patients, B cells make nonneutralizing cluster II antibodies that may mask or otherwise down-modulate B-cell responses to immunogenic regions of gp41 that could be recognized by B cells capable of producing antibodies like 2F5.

[1]  A. Trkola,et al.  A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.

[2]  R. Arora,et al.  A nonneutralizing anti-HIV Type 1 antibody turns into a broad neutralizing antibody when expressed on the surface of HIV type 1-susceptible cells. II. Inhibition of HIV type 1 captured and transferred by DC-SIGN. , 2006, AIDS research and human retroviruses.

[3]  G. Ciliberto,et al.  Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. , 2004, Journal of immunological methods.

[4]  D. Dimitrov,et al.  Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. , 2006, Biochemical and biophysical research communications.

[5]  J. Flamm,et al.  Severe CD4+ T-Cell Depletion in Gut Lymphoid Tissue during Primary Human Immunodeficiency Virus Type 1 Infection and Substantial Delay in Restoration following Highly Active Antiretroviral Therapy , 2003, Journal of Virology.

[6]  R. Mcconnell,et al.  Further Experimental Studies on the Prevention of Rh Haemolytic Disease , 1963, British medical journal.

[7]  Pojen P. Chen,et al.  The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes1 , 2007, The Journal of Immunology.

[8]  H. Dintzis,et al.  Studies on the immunogenicity and tolerogenicity of T-independent antigens. , 1983, Journal of immunology.

[9]  J. Groopman,et al.  Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. , 1985, Science.

[10]  G. McGaughey,et al.  HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. , 2003, Biochemistry.

[11]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Price,et al.  CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[13]  B. Haynes,et al.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates , 2006, Expert review of vaccines.

[14]  S. Zolla-Pazner,et al.  Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies , 1991, Journal of virology.

[15]  Renate Kunert,et al.  Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.

[16]  H. Katinger,et al.  Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. , 2006, AIDS research and human retroviruses.

[17]  Peter D. Kwong,et al.  Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.

[18]  Mario Roederer,et al.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection , 2005, Nature.

[19]  A. Trkola,et al.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.

[20]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[21]  W. Blattner,et al.  A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Pamela G. Guren,et al.  Candidates , 1982 .

[23]  Christine Hogan,et al.  Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[24]  E. Buratti,et al.  Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response. , 2000, Virology.

[25]  J. Sodroski,et al.  Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins , 2002, Journal of Virology.

[26]  H. Liao,et al.  An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120. , 2004, AIDS research and human retroviruses.

[27]  S. Zolla-Pazner,et al.  Recognition by Human Monoclonal Antibodies of Free and Complexed Peptides Representing the Prefusogenic and Fusogenic Forms of Human Immunodeficiency Virus Type 1 gp41 , 2000, Journal of Virology.

[28]  R. Brasseur,et al.  Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. , 1990, Intervirology.

[29]  M. Nussenzweig,et al.  Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. , 2001, The Journal of clinical investigation.

[30]  Hui Li,et al.  Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.

[31]  Dennis R. Burton,et al.  Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design , 2003, Journal of Virology.

[32]  B. Heyman,et al.  Antibody‐Mediated Regulation of the Immune Response , 2006, Scandinavian journal of immunology.

[33]  G. Rimmelzwaan,et al.  Refocusing neutralizing antibody response by targeted dampening of an immunological epitope , 2001 .

[34]  Robyn L Stanfield,et al.  Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Feng Gao,et al.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. , 2006, Virology.

[36]  R P Johnson,et al.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. , 1998, Science.

[37]  Renate Kunert,et al.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. , 2005, Immunity.

[38]  S. Calarota,et al.  Immunodominant glycoprotein 41 epitope identified by seroreactivity in HIV type 1-infected individuals. , 1996, AIDS research and human retroviruses.

[39]  J. Binley,et al.  Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[40]  G. McGaughey,et al.  Progress towards the development of a HIV-1 gp41-directed vaccine. , 2004, Current HIV research.

[41]  A. Neurath,et al.  Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistance to disease development. , 1990, AIDS research and human retroviruses.

[42]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[43]  L. Babiuk,et al.  CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. , 2002, Vaccine.

[44]  D. Birx,et al.  Monoclonal Antibodies to Phosphatidylinositol Phosphate Neutralize Human Immunodeficiency Virus Type 1: Role of Phosphate-Binding Subsites , 2006, Journal of Virology.

[45]  Jessica Yu,et al.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. , 2007, Vaccine.

[46]  Feng Gao,et al.  Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.

[47]  D. Pisetsky,et al.  Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant. , 2003, Clinical immunology.

[48]  M Anthony Moody,et al.  Antibody polyspecificity and neutralization of HIV-1: a hypothesis. , 2006, Human antibodies.

[49]  S. Zolla-Pazner,et al.  Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. , 1990, Journal of immunology.

[50]  T. Stout.  Prevention of Rh immunization. , 1969, Canadian journal of public health = Revue canadienne de sante publique.

[51]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[52]  M. Radic,et al.  Regulation of anti-phosphatidylserine antibodies. , 2003, Immunity.

[53]  C. E. Parker,et al.  Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 , 2001, Journal of Virology.

[54]  H. Dintzis,et al.  Inhibition of antibody formation by receptor cross‐linking: the molecular characteristics of inhibitory haptenated polymers , 1990, European journal of immunology.

[55]  Q. Sattentau,et al.  HIV-1 antibody — debris or virion? , 1997, Nature Medicine.

[56]  H. Katinger,et al.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.

[57]  J. Blomberg,et al.  Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. , 1988, Proceedings of the National Academy of Sciences of the United States of America.